Top

News & Events

Archive: 2019

News Archive

BioWednesday London: The J P Morgan Healthcare Conference: The Mood Music

06 February 2019
BioWednesday London: The J P Morgan Healthcare Conference: The Mood Music
Instinctif Office, London, UK

Read more »

BIA Gala Dinner 2019

24 January 2019
BIA Gala Dinner 2019
London, UK

Read more »

Abcam and the Loulou Foundation partner to develop key research tools for CDKL5 deficiency disorder

London and Cambridge, UK - Today, Abcam, a global innovator in life science reagents and tools, and the Loulou Foundation, a private UK-based foundation dedicated to the development of therapeutics for CDKL5 Deficiency Disorder, announced a research collaboration to discover new tools to advance research in this area of high unmet medical need.

Read more »

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the first milestone has successfully been achieved under Autifony’s option agreement with Boehringer Ingelheim. As announced previously, Boehringer Ingelheim acquired an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform in December 2017. Further details of the milestone were not disclosed.

Read more »

Clinigen Half Year trading update

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides an unaudited trading update for the six months ended 31 December 2018.

Read more »

Clinigen extends exclusive European clinical trial sourcing and supply agreement with Accord Healthcare

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Trial Service (‘CTS’) business has extended its exclusive European clinical trial supply agreement with Accord Healthcare (‘Accord’). Clinigen is also offering pharma companies an ‘on demand’ service to Accord’s products, a first for the industry.

Read more »

Instinctif Partners’ Life Science Practice Joins New Integrated Group of Specialist Life Science Advisors, Launched at JP Morgan 2019

London, UK – The Life Science Practice of Instinctif Partners, the business communications consultancy, is pleased to announce that it has joined with other sector specialist advisors in a new integrated healthcare solution, to be formally launched by the Bridgehead Group during the annual JP Morgan conference in San Francisco from 7-9 January 2019.

Read more »

Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda) is planning to evaluate the application of recently licensed Humabodies from Crescendo for the development of novel CAR-T therapeutics.

Read more »

US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies

Munich, Germany – Immatics, a leading company in the field of cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued the 100th patent to Immatics.

Read more »

Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces that it has entered into an agreement with VIB, a life sciences research institute in Flanders, Belgium, for an exclusive, worldwide license to VIB’s ‘Megabody’ technology.

Read more »

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapies targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved its first research milestone in its collaboration and license agreement with Gilead Sciences, Inc. (“Gilead”). The agreement, which was entered into in June 2018, grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave® investigational arenavirus-based immunization technologies for the development of immunotherapies against hepatitis B virus (HBV) and human immunodeficiency virus (HIV).

Read more »